A former senior executive at Taro Pharmaceuticals USA was indicted for his role in a wide-ranging conspiracy to fix prices for generic drugs, the third time that a high-ranking drug company official has been charged since federal authorities began their investigation several years ago.
Ara Aprahamian, a former vice president of sales and marketing at the company, was indicted for working with executives at another drug maker to increase prices and allocate customers for numerous drugs, including medicines used to treat and manage arthritis, seizures, pain, various skin conditions, and blood clots, according to the indictment that was filed in federal court in Philadelphia.
Both Aprahamian, who could not be reached for comment, and Taro had been previously named as defendants in a lawsuit filed last year by dozens of state attorneys general who have simultaneously been investigating price fixing in the generic drug industry. A spokesman for Taro, which is owned by Sun Pharmaceuticals, told us the company is aware of the “development,” but declined comment.
About the Author Reprints
Ah. I must observe that this event was certainly ‘in the cards.’ Now one must wonder, has the full hand been dealt or not?